View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Mar. 31, 2015	Jan. 08, 2016	Sep. 30, 2014
Document Type	10-K
Amendment Flag	true
Amendment Description	Helius Medical Technologies, Inc. (the “Company”) is filing this amendment on Form 10-K/A (this “Amendment”) to amend its Annual Report on Form 10-K for the fiscal year ended March 31, 2015, as filed on June 29, 2015 (the “Original Filing”), to restate (1) its consolidated financial statements as of and for the fiscal year ended March 31, 2015 and (2) selected financial data as of and for the fiscal year ended March 31, 2015, as a result of the Company not previously re-measuring the fair value of stock options awarded to non-employees that had not yet vested. See Note 12 “Restatement of Previously Issued Financial Statements” to the Company’s restated consolidated financial statements. In connection with the Original Filing, under the direction of our Chief Executive Officer and our Chief Financial Officer, our management evaluated our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, and concluded that our disclosure controls and procedures were ineffective as of March 31, 2015. Subsequently, the Company’s management has determined that the improper design of controls with respect to the calculation of the fair value of the Company’s share based compensation was a deficiency in its internal control over financial reporting resulting from the material weakness identified at March 31, 2015. Except as required to reflect the effects of the corrections for the items above, no additional modifications or updates have been made to the Original Filing and are set forth in this Amendment. Information not affected by these corrections remains unchanged and reflects the disclosure made at the time of the Original Filing. This Amendment does not describe other events occurring after the Original Filing, including exhibits, or modify or update those disclosures affected by subsequent events. This Amendment should be read in conjunction with the Company’s filings made with the Securities and Exchange Commission subsequent to the filing of the Original Filing, as information in such reports and documents may update or supersede certain information contained in this Amendment. The certifications of the Company’s Chief Executive Officer and Chief Financial Officer, and the consents of each of its independent registered public accounting firms are attached to this Amendment as Exhibits 31.1, 31.2, 32.1, 23.1 and 23.2, respectively.
Document Period End Date	Mar. 31, 2015
Trading Symbol	hsm
Entity Registrant Name	HELIUS MEDICAL TECHNOLOGIES, INC.
Entity Central Index Key	0001610853
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		72,193,209
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Public Float			$ 59,502,069
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY

Interim Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2015	Mar. 31, 2014
Current assets
Cash and cash equivalents	$ 418,893	$ 15,968
Short-term investment	378,000	0
Receivables	8,833	0
Prepaid expenses	410,621	300,000
Total current assets	1,216,347	315,968
TOTAL ASSETS	1,216,347	315,968
Current liabilities
Accounts payable and accrued liabilities	1,197,804	215,921
Convertible debenture	0	368,024
Total current liabilities	1,197,804	583,945
Derivative liability	1,581,444	0
TOTAL LIABILITIES	2,779,248	583,945
CAPITAL (DEFICIT)
Common stock (Unlimited Class A common shares authorized); (63,104,788 shares outstanding at March 31, 2015 and 32,070,052 at March 31, 2014)	16,358,093	8,510,000
Additional paid-in capital	2,434,552	807,157
Shares to be issued	39,545	0
Accumulated other comprehensive income	(971,640)	0
Accumulated deficit	(19,423,451)	(9,585,134)
TOTAL SHAREHOLDERS' EQUITY (CAPITAL DEFICIT)	(1,562,901)	(267,977)
TOTAL LIABILITIES & CAPITAL (DEFICIT)	$ 1,216,347	$ 315,968

Interim Condensed Consolidated Balance Sheets (Parenthetical) - shares	Mar. 31, 2015	Mar. 31, 2014
Common Stock, Shares Authorized
Common Stock, Shares, Outstanding	63,104,788	32,070,052

Interim Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Operating Expenses
Advertising, marketing, & IR	$ 774,400	$ 0	$ 0
Audit & accounting	71,340	0	0
Consulting fees	1,358,070	807,385	4,252,800
Insurance	75,425	0	0
Legal fees	1,478,766	33,966	14,192
Meals & travel	272,338	22,860	376
Office & general	166,282	8,137	482
Professional fees	14,136	0	0
Research & development	4,500,073	171,781	4,250,000
Transfer agent & regulatory	104,214	0	0
Wages and salaries	993,400	23,155	0
Loss from operations	(9,808,444)	(1,067,284)	(8,517,850)
Other items
Interest expense	(176,488)	0	0
Interest income	20,074	0	0
Change in fair value of derivative liability	(739,375)	0	0
Foreign exchange gain (loss)	865,916	0	0
Total other income (loss)	(29,873)	0	0
Net loss for the period	(9,838,317)	(1,067,284)	(8,517,850)
Other comprehensive income (loss)
Translation adjustments	(971,640)	0	0
Comprehensive loss for the period	$ (10,809,957)	$ (1,067,284)	$ (8,517,850)
Basic and diluted loss per common stock	$ (0.17)	$ (0.03)	$ (0.27)
Weighted average number of common stock outstanding - basic & diluted	57,048,406	32,070,052	32,070,052

Interim Condensed Consolidated Statements of Capital Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Shares to be Issued [Member]	Accumulated Deficit [Member]	Accumulated other comprehensive income (loss)[Member]	Total
Beginning Balance at Jan. 22, 2013	$ 0
Shares issued for cash, intellectual property and services	$ 8,510,000					$ 8,510,000
Shares issued for cash, intellectual property and services (Shares)	32,070,052
Net loss for the period				$ (8,517,850)		(8,517,850)
Ending Balance at Mar. 31, 2013	$ 8,510,000			(8,517,850)		(7,850)
Ending Balance (Shares) at Mar. 31, 2013	32,070,052
Stock-based compensation on 654,481 options granted		$ 173,873				173,873
Stock-based compensation on 2,300,000 options granted		560,082				560,082
Stock-based compensation on 275,550 options granted		73,202				73,202
Share issuance cost						0
Net loss for the period				(1,067,284)		(1,067,284)
Ending Balance at Mar. 31, 2014	$ 8,510,000	807,157		(9,585,134)		(267,977)
Ending Balance (Shares) at Mar. 31, 2014	32,070,052
Stock-based compensation on 2,300,000 options granted		50,303				50,303
Shares issued to consultant for option exercise 1	$ 717					717
Shares issued to consultant for option exercise 1 (Shares)	2,300,000
Shares issued to consultant for option exercise 2	$ 290					290
Shares issued to consultant for option exercise 2 (Shares)	930,031
Fair value of options allocated to share capital on exercise of options	$ 857,460	(857,460)
Recapitalization of Helius Medical Technologies, Inc.		162,890				162,890
Recapitalization of Helius Medical Technologies, Inc. (Shares)	10,000,000
Issuance of common stock for private placement	$ 6,437,041	578,961				7,016,002
Issuance of common stock for private placement (Shares)	15,240,000
Share issuance cost	$ (447,515)	67,709				(379,806)
Beneficial conversion feature		176,488				176,488
Stock-based compensation on 3,370,000 options granted		1,227,724				1,227,724
Conversion of debenture	$ 1,000,100					1,000,100
Conversion of debenture (Shares)	2,564,705
Stock-based compensation on 400,000 options granted		135,564				135,564
Stock-based compensation on 100,000 options granted 1		74,190				74,190
Stock-based compensation on 100,000 options granted 2		43,229				43,229
Stock-based compensation on 100,000 options granted 3		41,987				41,987
Fair value of vested non-employee options reallocated to derivative liability		(74,190)				(74,190)
Private placement proceeds			$ 39,545			39,545
Net loss for the period				(9,838,317)		(9,838,317)
Translation adjustments					$ (971,640)	(971,640)
Ending Balance at Mar. 31, 2015	$ 16,358,093	$ 2,434,552	$ 39,545	$ (19,423,451)	$ (971,640)	$ (1,562,901)
Ending Balance (Shares) at Mar. 31, 2015	63,104,788

Interim Condensed Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities
Net loss for the period	$ (9,838,317)	$ (1,067,284)	$ (8,517,850)
Adjustments for:
Change in fair value of derivative liability	739,375	0	0
Stock-based compensation	2,340,876	807,157	8,500,000
Accretion of beneficial conversion feature	176,488	1,344	0
Changes in non-cash working capital items:
Receivables	(8,945)	0	0
Accounts payable	979,040	210,085	5,836
Prepaid expenses	(110,873)	(300,000)	0
Foreign exchange re-measurement	(598,929)	0	0
Net cash used in operating activities	(6,321,285)	(348,698)	(12,014)
Cash flows from Investing Activities
Purchase of short-term investment	(378,000)	0	0
Net cash used in Investing Activities	(378,000)	0	0
Cash flows from financing activities
Cash acquired on recapitalization	23,904	0	0
Proceeds from issuance of shares	7,017,009	0	10,000
Share issuance cost	(379,806)	0	0
Proceeds from shares to be issued	39,545	0	0
Proceeds from bridge loan	150,000	0	0
Short term loan	0	(2,231)	2,231
Proceeds from issuance of convertible debt	632,076	366,680	0
Net cash provided by financing activities	7,482,728	364,449	12,231
Effect of Foreign Exchange Rate Changes on Cash	(380,518)	0	0
Net change in cash and cash equivalents	402,925	15,751	217
Cash and cash equivalents, beginning of the period	15,968	217	0
Cash and cash equivalents, end of the period	418,893	15,968	217
Supplemental information of cash flows
Interest paid in cash	11,144	0	0
Income taxes paid in cash	0	0	0
Total supplemental information of cash flows	$ 11,144	$ 0	$ 0

BASIS OF PRESENTATION

12 Months Ended

Mar. 31, 2015

BASIS OF PRESENTATION [Text Block]

1.	NATURE AND CONTINUANCE OF OPERATIONS

Helius Medical Technologies, Inc. ("Helius" or the "Company") is in the development stage and engaged primarily in the medical technology industry focused on neurological wellness. The Company’s planned principal operations include the development, licensing and acquisition of unique and non-invasive platform technologies to amplify the brain’s ability to heal itself.

The Company was incorporated in British Columbia, Canada, on March 13, 2014. On May 28, 2014, the Company completed a continuation via a plan of arrangement whereby the Company moved from being a corporation governed by the British Columbia Corporations Act to a corporation governed by the Wyoming Business Corporations Act. The Company’s head office is located at 41 University Drive, Suite 400, Newtown, PA, USA 18940.

The Company is listed on the Canadian Securities Exchange (the "CSE") and began trading on June 23, 2014, under the ticker symbol "HSM". The Company also began trading on the OTCQB under the ticker symbol "HSDT" on February 10, 2015.

On June 13, 2014, the Company completed its acquisition of 100% of the issued and outstanding shares of Neurohabilitation Corporation ("Neuro"), a private company incorporated in Delaware, USA, on January 22, 2013. Prior to the transaction, Helius was a non-operating public shell company. Accordingly, for financial reporting purposes, this transaction was deemed to be a capital transaction in substance and recorded as a reverse recapitalization of Neuro whereby Neuro is deemed to be the continuing, surviving entity for accounting purposes, but through reorganization, has deemed to have adopted the capital structure of Helius. Because the acquisition was considered a reverse recapitalization for accounting purposes, the combined historical financial statements of Neuro became the historical financial statements and from the completion of the acquisition on June 13, 2014, the financial statements have been prepared on a consolidated basis. The assets and liabilities of Neuro have been brought forward at their book value and no goodwill has been recognized in connection with the transaction.

The Company had a wholly-owned subsidiary, 0995162 B.C. Ltd, which was dissolved on October 23, 2014. On December 17, 2014, Neuro incorporated a wholly-owned subsidiary, Helius Medical Technologies (Canada), Inc. ("Helius Canada"). The financial information is presented in United States Dollars.

SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Mar. 31, 2015

SIGNIFICANT ACCOUNTING POLICIES [Text Block]

2.	SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Liquidity

The Company’s consolidated financial statements have been presented in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") and the rules and regulations of the Securities and Exchange Commission ("SEC") that are published at the time of preparation and that are effective or available on March 31, 2015. The Company has incurred a net loss of $9,838,317 for the year ended March 31, 2015 and, as of March 31, 2015, the Company has an accumulated deficit of $19,423,451 (March 31, 2014 - $9,585,134 ; March 31, 2013 - $8,517,850). Until the Company generates a level of revenue to support its cost structure, the Company expects to continue to incur substantial operating losses and net cash outflows. While the Company had cash and cash equivalents of $418,893 as of March 31, 2015 (March 31, 2014 - $15,968), management does not believe these resources will be sufficient to meet the Company’s operating and capital needs for the ensuing fiscal year.

The Company intends to fund ongoing activities by utilizing current cash and cash equivalents and by raising additional capital though equity or debt financings. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditure or sell certain assets, including intellectual property asset. This material uncertainty gives rise to substantial doubt about the Company’s ability to continue as a going concern.

Use of Estimates

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Significant estimates include valuation of share-based payment transactions, compensation expense related to shares issued for services, valuation of options and warrants and deferred income tax asset valuation allowances. Actual outcomes could differ from these estimates. Financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and the revision affects both the current and future periods.

Principles of Consolidation

The consolidated financial statements include the historic accounts of Neuro and are consolidated with Helius and its subsidiaries beginning June 13, 2014. All intercompany balances and transactions have been eliminated in consolidation.

Cash and Cash Equivalents

Cash and cash equivalents comprise cash at banks and on hand, and short-term highly liquid investments that have an insignificant interest rate risk and an original maturity of 3 months or less.

Short-term investment

The short-term investments are readily redeemable term deposits held at the bank. As at March 31, 2015, the short-term investment consists of a one year guaranteed investment certificate ("GIC") in the amount of $378,000 yielding 0.25% per annum. Due to the Company’s intention to have the short-term investment available for liquidity purposes, it has been classified as available-for-sale and recorded at its fair value. Any unrealized gains or losses are excluded from earnings and are recorded in other comprehensive income.

Concentrations of Credit Risk

The Company is subject to credit risk in respect of its cash and short-term investment. Amounts invested in such instruments are limited by credit rating, maturity, industry group, investment type and issuer. The Company is not currently exposed to any significant concentrations of credit risk from these financial instruments. The Company seeks to maintain safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements and a competitive after-tax rate of return.

Stock-Based Compensation

The Company accounts for all stock-based payments and awards under the fair value based method. The Company recognizes its stock-based compensation using the accelerated attribution method.

Stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments. The fair value of the stock-based payments to non-employees that are fully vested and non-forfeitable as at the grant date are measured and recognized at that date.

The Company accounts for the granting of share purchase options to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their vesting period with a corresponding increase to additional capital surplus. Upon exercise of share purchase options, the consideration paid by the option holder, together with the amount previously recognized in additional paid-in capital is recorded as an increase to share capital. Share purchase options granted to employees are accounted for as liabilities when they contain conditions or other features that are indexed to other than a market, performance or service condition.

The Company uses the Black-Scholes option pricing model to calculate the fair value of share purchase options. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes in these assumptions can materially affect the fair value estimate.

Foreign Exchange

The functional currency of the Company and Helius Canada is the Canadian Dollar and the functional currency of Neuro is the United States Dollars. The Company’s reporting currency is the US dollar.

The assets and liabilities of the Company and Helius Canada are translated into U.S. dollars using year-end exchange rates; income and expenses are translated using the average exchange rates for the reporting period. Unrealized foreign currency translation adjustments are deferred in accumulated other comprehensive loss, a separate component of shareholders’ equity. The foreign exchange adjustment in the books of Neuro relating to inter-company advances from Helius that are denominated in Canadian dollars is recorded in the Statement of Loss. At March 31, 2015, Neuro recorded a foreign exchange gain of $573,917 in respect of this adjustment and which is reflected in the consolidated statement of loss for the year ended March 31, 2015.

Net Loss per Common Share

Basic net earnings (loss) per share is computed by dividing net earnings (loss) available to common stockholders by the weighted average number of outstanding common stock for the period, without consideration for common stock equivalents. Diluted net income (loss) per common share includes both the weighted-average number of common shares outstanding for the period plus the potentially dilutive securities from stock options and warrants outstanding determined using the treasury-stock method and the if-converted method, as applicable. As at March 31, 2015, there were 4,920,000 options (March 31, 2014 - 3,230,031 ; March 31, 2013 - nil) outstanding and 8,444,400 warrants (March 31, 2014 - nil; March 31, 2013 - nil) outstanding which have not been included in the weighted average common stock outstanding as these were anti-dilutive.

Fair Value of Financial Assets and Liabilities

The Company’s financial instruments consist primarily of cash and cash equivalents, short-term investment and accounts payable and accrued liabilities. The book values of these instruments approximate their fair values due to the immediate or short-term nature of those instruments.

ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value;

Level 1 - Quoted prices in active markets for identical assets or liabilities;

Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and

Level 3 - Unobservable inputs that are supported by little or no market activity, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

Cash and cash equivalents and short-term investment are measured using Level 1 inputs.

The Company had certain Level 3 liabilities required to be recorded at fair value on a recurring basis in accordance with US GAAP as at March 31, 2015. As at March 31, 2015, the Company’s Level 3 liabilities consisted of the grant of share purchase options granted to non-employees. The resulting Level 3 liabilities have no active market and are required to be measured at their fair value each reporting period based on information that is unobservable.

A summary of the Company’s Level 3 liabilities for the fiscal years ended March 31, 2015 and 2014 are as follows:

	March 31,2015	March 31, 2014
	$	$

Non-employee options (Note 6(a))
Beginning fair value	-	-
Issuance	767,879	-
Reallocation of vested non-employee options	74,190	-
Change in fair value	739,375	-
Ending fair value of Level 3 liability	1,581,444	-

Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances (for example, when there is evidence of impairment). There were no assets or liabilities measured at fair value on a nonrecurring basis during the periods ended March 31, 2015 and 2014.

Income Taxes

The Company accounts for income taxes using the asset and liability method. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized.

The Company has adopted the provisions of FASB ASC 740 "Income Taxes" regarding accounting for uncertainty in income taxes. The Company initially recognizes tax provisions in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of the tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations. When applicable, the Company classifies penalties and interest associated with uncertain tax positions as a component of income tax expense in its consolidated Statement of Income (Loss) and Comprehensive Income (Loss).

Research and Development Expenses

Research and development (R&D) expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations and materials and supplies. R&D costs are charged to operations when they are incurred.

Derivative Liabilities

The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statement of loss. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet date.

The Company uses the Black-Scholes option valuation model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement.

Recent Accounting Pronouncements

In August 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable) and to provide related footnote disclosures. The ASU provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The ASU is effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016, which for the Company is April 1, 2017. Early adoption is permitted. The Company does not intend to early adopt this standard. The adoption of this standard will not have a material impact on the Company's financial position or results of operations.

In June 2014, the FASB issued ASU No. 2014-10, "Development Stage Entities" ("ASU 2014-10") which removes the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the update eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU No. 2014-10 is effective for fiscal years and interim periods beginning after December 15, 2014, with early adoption permissible. The Company early adopted ASU 2014-10 allowing the financial statements to be cast without the inception to date information and without references to the development stage.

The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties , is applicable to entities that have not commenced planned principal operations. The central feature of the guidance disclosure requirements is that required disclosures are limited to matters significant to a particular entity. The disclosures focus primarily on risks and uncertainties that could significantly affect the amounts reported in the financial statements in the near term or the near-term functioning of the reporting entity.

In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 781): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period . This update requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. This update is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2015, which for the Company is April 1, 2016. Early adoption is permitted. Entities may apply the amendments in this update either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of this standard will not have a material impact on the Company's financial position or results of operations.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) . This update outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. This new guidance is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016, which for the Company is April 1, 2017; early adoption is not permitted. Entities have the option of using either a full retrospective or a modified approach to adopting the guidance. The Company does not anticipate that the adoption of this update will have a material impact on its financial position or results of operations.

RECAPITALIZATION

12 Months Ended

Mar. 31, 2015

RECAPITALIZATION [Text Block]

3.	RECAPITALIZATION

On June 13, 2014 the Company completed a recapitalization transaction where the Company acquired 100% of the issued and outstanding shares of Neuro. In exchange, the Company issued a total of 35,300,083 shares to the shareholders of Neuro which merged with a wholly-owned subsidiary of the Company, HMT Mergersub, for the purpose of the three-corner amalgamation. As a result, the former Neuro shareholders owned the majority of the outstanding shares of the Company upon completion of the transaction. Prior to the recapitalization transaction, the Company did not meet the definition of a business. Thus, the transaction is considered to be a capital transaction of Neuro accompanied by a recapitalization.

The ongoing Company has adopted the name Helius Medical Technologies, Inc. These financial statements present the results of Neuro with the exception of common stock which has been retroactively restated to reflect the Recapitalization (see Note 6). In connection with the Recapitalization, the Company advanced Neuro an unsecured loan in the amount of $150,000 (the "Bridge Loan"). The Bridge Loan was for a term of one year commencing on May 30, 2014, and was payable in a lump sum at the end of the term. The Bridge Loan bears interest at a rate of 8% per annum.

The net assets of Helius acquired were as follows,

Cash and cash equivalents	$	23,904
Receivables		1,644
Bridge loan receivable		150,000
Prepaid expenses		5,970
Accounts payable and accrued liabilities		(18,628	)
	$	162,890

The recapitalization transaction reflects a credit to additional paid-in capital of $162,890, the carrying value of the net assets of Helius at the time of the reverse merger.

In connection to the completion of the transaction, the Company completed a private placement of 15,240,000 units at CAD $0.50 per unit for a total of $7,016,002 (CAD $7,620,000) (Note 5). Each unit consisted of one common share of the Company and one-half of a share purchase warrant. Each whole share purchase warrant is exercisable at CAD $1.00 for a period of twenty-four months. In respect of this private placement, the Company paid aggregate finders’ fees of $379,806 (CAD $412,200) and issued 824,400 finders’ warrants. Each finder’s warrant is exercisable at CAD $1.00 per share for a period of two years.

CONVERTIBLE DEBENTURE

12 Months Ended

Mar. 31, 2015

CONVERTIBLE DEBENTURE [Text Block]

4.	CONVERTIBLE DEBENTURE

On February 19, 2014, the Company entered into a securities purchase agreement where the Company agreed to sell and issue a note with annual simple interest at 8% (the "Debenture"). A total of $1,000,100 in principal had been received.

Upon completion of a qualified financing in which the Company was to raise at least $2,000,000, the debenture would automatically convert into equity securities of the Company at a price per share equal to 85% of the price per share of the qualified financing. If a qualified financing did not occur on or before the maturity date, at the option of the Company’s board of directors, the outstanding balance of the debenture would be converted into the Company’s equity securities at a conversion price per common stock determined using a valuation of $8.5 million and the number of shares outstanding at that date.

On June 13, 2014, the Debenture matured on the closing of the Company’s qualified financing. Upon completion of the qualified financing, the Debenture automatically converted into equity securities of the Company at a price per share equal to 85% of the price per share of the qualified financing.

The conversion option of the Debenture was accounted for as a contingent beneficial conversion feature valued at $176,488 which was recorded as interest expense in the Statement of Comprehensive Loss on settlement of the contingency.

Upon conversion of the Debenture, the Company issued a total of 2,564,705 common shares. In addition, the Company paid the Debenture holders $11,131 with respect to the accrued and unpaid interest outstanding.

COMMON STOCK

12 Months Ended

Mar. 31, 2015

COMMON STOCK [Text Block]

5.	COMMON STOCK

Authorized:

Unlimited Class A common shares without par value.

Each Class A common share is entitled to have the right to vote at any shareholder meeting on the basis of one vote per share. Each Class A share held entitles the holder to receive dividends as declared by the directors. In the event of the liquidation, dissolution or winding-up of the Company other distribution of assets of the Company among its shareholders for the purposes of winding-up its affairs or upon a reduction of capital the holders of the Class A common shares shall, share equally, share for share, in the remaining assets and property of the Company.

Class B common shares and Class A preferred shares were deleted from the list of classes of shares the Company is authorized to issue by way of amendment to the Company’s articles effective June 12, 2014.

The Company is subject to a stockholders agreement, which places certain restrictions on the Company’s stock and its stockholders. These restrictions include approvals prior to sale or transfer of stock, a right of first refusal to purchase stock held by the Company and a secondary right of refusal to stockholders, right of co-sale whereby certain stockholders may be enabled to participate in a sale of other stockholders to obtain the same price, term and conditions on a pro-rata basis, rights of first offer of new security issuances to current stockholders on a pro-rata basis and certain other restrictions.

Prior to the Recapitalization

The number of securities below reflects the Recapitalization and the exchange ratio retrospectively.

On January 22, 2013, the Company issued a total of 16,035,026 shares to Advanced NeuroRehabilitation LLC ("ANR") for cash proceeds of $5,000 and an exclusive license right to ANR’s patent pending technology and knowhow valued at $4.25 million per an independent valuation report. The valuation expert was engaged to assess the valuation of the costs incurred to date as well as the ongoing costs which would be required to bring the product to commercialization, discounted to the date of purchase. The Company recorded the $4.25 million exclusive license right as research and development expense per the Company’s accounting policy.

On January 22, 2013, the Company also issued a total of 16,035,026 shares to MPJ Healthcare LLC ("MPJ") for cash proceeds of $5,000. In addition, the Company recorded $4.25 million of stock based compensation expense.

On May 1, 2014, 2,300,000 options were exercised for 2,300,000 common shares for total proceeds of $717.

On May 11, 2014, 930,031 options were exercised for 930,031 common shares for total proceeds of $290.

In conjunction with the private placement completed on May 30, 2014 and recapitalization transaction completed on June 13, 2014 (Note 3), the Company entered into an escrow agreement with each of ANR, MPJ and the Company’s transfer agent whereby the 32,070,052 common shares issued to ANR and MPJ were placed in escrow in accordance with Canadian securities regulations. These shares were scheduled to be released from escrow over a period of 3 years from the date of the escrow agreement with 10% of the shares placed in escrow released on the completion date of the reverse merger and with 15% of the remaining outstanding balance of shares released every 6 months thereafter. The release of the escrow is not subject to any performance conditions and therefore not considered to be compensatory in nature. In addition, on their release, the value recorded in respect of these shares will not change and they are included in the calculation of earnings per share.

After the Recapitalization

Upon completion of the Recapitalization, the Company issued a total of 35,300,083 shares to the shareholders of Neuro. (Note 3)

In connection with the Recapitalization, the Company also closed a non-brokered private placement (the "Private Placement") at CAD $0.50 per unit of 15,240,000 units raising $7,016,002 (CAD $7.62 million) on May 30, 2014 (Note 3). Each unit consists of one common stock of the Company and one half of a warrant of the Company where one full warrant is exercisable for 2 years at CAD $1.00 into one common stock. The fair value of the warrants issued was determined using the Black Scholes model and the Company used the relative fair value method to allocate $578,961 of the gross proceeds to Additional Paid-in Capital to account for the warrants issued.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

SHARE BASED PAYMENTS

12 Months Ended

Mar. 31, 2015

SHARE BASED PAYMENTS [Text Block]

6.	SHARE BASED PAYMENTS

(a)	Stock options

The number of securities below reflects the Recapitalization and the exchange ratio retrospectively.

The Company has a stock option plan whereby the Company is authorized to grant up to 12,108,016 options. Vesting and the term of an option is determined at the discretion of the Board of Directors of the Company.

On April 1, 2013, the Company granted a consultant company 930,031 options for 10 years upon completion of certain services in accordance with a consulting agreement to lead the design and manufacturing program of the Company’s technology. On December 4, 2013, 654,481 options vested. On May 11, 2014, all these options had vested and were exercised for 930,031 common shares.

On October 30, 2013, the Company granted 2,300,000 options exercisable for 10 years to a consultant company for strategic business advisory services which are to vest upon completion of two milestones. On February 11, 2014, 1,150,000 options were vested upon completion of the first of the two milestones. On April 28, 2014, the remaining 1,150,000 options were vested upon completion of the second milestone. On May 1, 2014, all 2,300,000 options were exercised for 2,300,000 shares.

On June 19, 2014, the Company granted 3,520,000 options to directors, officers, and consultants exercisable at CAD $0.60 for 5 years. One third of these options vested immediately upon granting. The remaining two thirds of the options will vest on June 19, 2015, and June 19, 2016 respectively.

On June 20, 2014, the Company granted 250,000 options to an investor relations consultant exercisable at CAD $0.60 for 5 years. 12.5% of these options vested immediately upon granting. The remaining 87.5% will vest at a rate of 12.5% every three months beginning September 20, 2014.

On July 14, 2014, the Company granted 100,000 options to a consultant exercisable at CAD $2.52 for 3 years. 25% of these options vested immediately upon granting. The remaining options will vest at a rate of 25% on September 30, 2014, December 31, 2014, and March 31, 2015, respectively.

On December 8, 2014, the Company granted 450,000 options to members of its scientific advisory board exercisable at CAD $2.92 for 5 years. All of these options vested immediately upon granting.

On December 8, 2014, the Company granted 100,000 options to a new director exercisable at CAD $2.92 for 5 years. One third of these options vested immediately upon granting. The remaining two thirds of the options will vest on December 8, 2015, and December 8, 2016 respectively.

On December 8, 2014, the Company granted 400,000 options to its new Chief Medical Officer exercisable at CAD $2.96 for 5 years. 25% of these options vested immediately upon granting. The remaining options will vest at a rate of 25% on June 8, 2015, December 8, 2015, and June 8, 2016, respectively.

On March 16, 2015, the Company granted 100,000 options to a new director exercisable at CAD $3.20 for 5 years. One third of these options vested immediately upon granting. The remaining two thirds of the options will vest on March 16, 2016, and March 16, 2017 respectively.

The continuity of stock options for the period ended March 31, 2015 and 2014 is as follows:

				Weighted
				Average		Aggregate
				Exercise Price		Intrinsic Value
	Number			(CAD)		(CAD)
Balance, March 31, 2013	-			-
Granted	3,230,031		$	0.0003	$	-

Balance, March 31, 2014	3,230,031		$	0.0003	$	-
Granted	4,920,000		$	1.14	$	-
Exercised	(3,230,031	)	$	0.0003	$	-

Balance outstanding at March 31, 2015	4,920,000		$	1.14	$	10,120,000

Balance exercisable at March 31, 2015	2,015,001		$	1.41	$	7,757,667

The options outstanding and exercisable at March 31, 2015 are as follows:

		Options
		outstanding
		remaining
		contractual life		Exercise		Grant date fair	Number of options
Number of options	Expiry date	(years)		Price (CAD)		value (CAD)	exercisable

3,520,000	June 18, 2019	4.22	$	0.60	$	0.23	1,173,333
250,000	June 20, 2019	4.22	$	0.60	$	0.23	125,000
100,000	July 14, 2017	2.29	$	2.52	$	1.06	100,000
450,000	December 8, 2019	4.69	$	2.92	$	1.65	450,000
100,000	December 8, 2019	4.69	$	2.92	$	1.49	33,334
400,000	December 8, 2019	4.69	$	2.96	$	1.56	100,000
100,000	March 16, 2020	4.96	$	3.20	$	1.61	33,334
4,920,000							2,015,001

The weighted average grant date fair value of stock options granted during the year ended March 31, 2015 of CAD$0.54 was estimated using the Black-Scholes option pricing model with the following weighted average assumptions: stock price - CAD$1.06 ; exercise price - CAD$1.14 ; expected risk-free interest rate - 1.08%; expected life - 4.1 years; expected volatility - 67.85% and expected dividend rate - 0%. The Company has adopted the simplified method prescribed by the SEC in SAB Topic 14 in respect of estimating the expected term of its stock options as its limited share purchase option history does not provide a reasonable basis to estimate the expected terms. As well, expected volatility was determined by reference to the average volatility rates of other companies in the same industry due to the Company’s limited trading history.

Non-Employee Stock Options

In accordance with the guidance of ASC 815-40-15, stock options awarded to non-employees that are performing services for Neuro are required to be accounted for as derivative liabilities once the services have been performed and the options have vested because they are considered not to be indexed to the Company’s stock due to their exercise price being denominated in a currency other than Neuro’s functional currency. Stock options awarded to non-employees that are not vested are accounted for as equity awards until the terms associated with their vesting requirements have been met.

The non-employee stock options are accounted for at their respective fair values and are summarized as follows for the years ended March 31, 2015 and 2014:

	2015	2014
	$	$

Fair value of non-employee options, beginning of the period	-	-
Fair value of non-employee options, at issuance	767,879	-
Reallocation of vested non-employee options	74,190
Change in fair value of non-employee stock options during the period	739,375	-

Fair value of non-employee options, end of the period	1,581,444	-

The non-employee options are required to be re-valued with the change in fair value of the liability recorded as a gain or loss on the change of fair value of derivative liability and included in other items in the Company’s Consolidated Statements of Loss at the end of each reporting period. The fair value of the options will continue to be classified as a liability until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as a liability.

Stock-based compensation related to the grant of each of employee and non-employee options is summarized as follows for the years ended March 31, 2015 and 2014 and for the period from January 22, 2013 (date of incorporation) to March 31, 2013:

Date of grant	Number		2015	2014	2013
			(restated) $	$	$

Employee options
April 1, 2013	930,031		-	247,075	-
October 30, 2013	2,300,000		50,303	560,082	-
June 19, 2014	1,970,000		165,996	-	-
July 14, 2014	75,000		74,190	-	-
December 8, 2014	100,000		43,229	-	-
December 8, 2014	400,000		135,564	-	-
March 16, 2015	100,000		41,987	-	-
	5,875,031		511,269	807,157	-
Options exercised	(3,230,031	)	-	-	-
	2,645,000		511,269
Non-employee
options
June 19, 2014	1,800,000		1,158,822	-	-
July 14, 2014	25,000		24,730	-	-
December 8, 2014	450,000		646,055	-	-
	2,275,000		1,824,607	-	-

	4,920,000		2,340,876	807,157	-

Share-based payments are classified in the Company’s Statement of Loss as follows for the years ended March 31, 2015 and 2014 and for the period from January 22, 2013 (date of incorporation) to March 31, 2013:

	2015	2014	2013
	(restated) $	$	$

Consulting fees	1,167,281	807,157	4,250,000
Research and development	721,601	-	4,250,000
Wages and salaries	451,994	-

	2,340,876	807,157	8,500,000

At March 31, 2015, the aggregate unamortized stock based compensation cost remaining to be recognized totals $2,303,664 with $2,070,656 expected to be recognized in the year ended March 31, 2016 and $233,008 expected to be recognized in the fiscal year ended March 31, 2017.

The Company used the Black Scholes option pricing model to estimate the fair value of the options as the fair value of the services provided could not be reliably calculated. The following assumptions were used:

		March 31, 2015	March 31, 2014
Stock Price	CAD$	0.50 - 3.18	0.27
Exercise Price	CAD$	0.60 - 3.20	0.0003
Risk-free interest rate (%)		0.53 - 1.42	1.20 - 1.65
Dividend yield (%)		0.00	0.00
Expected volatility (%)		67.85	97.73 - 116.82
Expected option life (years)		3.00 - 5.00	4.33 - 5.00

The Black Scholes option pricing model was developed for use in estimating the fair value of share options that have no vesting provisions and are fully transferable. Also, option-pricing models require the use of estimates and assumptions including the expected volatility. The Company uses expected volatility rates which are based upon the average volatility rates of other companies in the same industry, due to the Company’s limited history. The Company based the current stock price on the value per shares issued to date. Changes in the underlying assumptions can materially affect the fair value estimates.

(b)	Share Purchase Warrants

The Company closed its Private Placement at CAD $0.50 per unit of 15,240,000 units raising CAD $7.62 million on May 30, 2014. Each unit consists of one common stock of the Company and one half of a warrant of the Company where one full warrant is exercisable for 2 years at CAD $1.00 into one common share.

The proceeds of the private placement were allocated between the common shares and the warrants on a relative fair value basis with an amount of $578,961 allocated to the warrants. In addition, the Company issued 824,400 finder’s warrants exercisable at CAD $1.00 for 2 years. The fair value of the finders’ warrants was determined to be $67,709.

The fair values attributable to the warrants were determined by using the Black Scholes model based on the following assumptions:

Stock price		CAD$0.50
Exercise price		CAD$1.00
Risk-free interest rate (%)		1.09
Dividend yield (%)		-
Expected volatility (%)		67.85
Expected option life (years)		1.17

The continuity of warrants for the period ended March 31, 2015 and 2014 is as follows:

			Warrants Outstanding
	Number of		Weighted Average Exercise Price
	warrants
Balance, March 31, 2013 and 2014	-	$	-
Granted	8,444,400	$	CAD1.00
Balance, March 31, 2015	8,444,400	$	CAD1.00

The warrants outstanding and exercisable at March 31, 2015 are as follows:

		Grant date
Number of warrants outstanding	Exercise Price (CAD)	Fair value (CAD)	Expiry Date
7,620,000	$1.00	$0.0899	May 30, 2016
824,400	$1.00	$0.0899	May 30, 2016

INCOME TAXES

12 Months Ended

Mar. 31, 2015

INCOME TAXES [Text Block]

7.	INCOME TAXES

The components of net loss for the years ended March 31, 2015 and 2014 and for the period from January 22, 2013 (date of incorporation) to March 31, 2013 are as follows:

	2015	2014	2013
	$	$	$

U.S	9,301,988	1,067,284	8,517,850
Non-U.S.	536,329	-	-

	9,838,317	1,067,284	8.517,750

A reconciliation of the income tax provision computed at statutory rates to the reported income tax provision for the years ended March 31, 2015 and 2014 is as follows:

	2015	2014	2013
	$	$	$
Statutory tax rate	34.00%	25.00%	25.00%
Loss before income taxes	(9,838,317)	(1,067,284)	(8,517,850)
Expected income tax recovery	(3,345,000)	(270,000)	(2,151,000)
Increase (decrease) in income tax recovery resulting from:
Derivative liability	251,000	-
Share based payments	796,000	275,000	2,890,000
Other permanent difference	12,000	-	-
Share issue costs	(140,000)	-
Effect of change in statutory rate	(41,000)	(93,000)	(745,000)
Effect of foreign exchange	89,000	-
Foreign income taxed at foreign rate	14,000	-
Increase in valuation allowance	2,364,000	88,000	6,000
Income tax expense	-	-	-

The significant components of the Company’s deferred income tax assets and liabilities after applying enacted corporate tax rates at March 31, 2015 and 2014 are as follows:

	2015		2014		2013
	$		$		$


Deferred income tax assets (liabilities)
Operating losses carried forward	2,074,000		94,000		6,000
Intangible costs	285,000
Share issuance costs	99,000		-
Valuation allowance	(2,458,000	)	(94,000	)	(6,000	)


Net deferred income tax asset	-		-		-

At March 31, 2015, the Company has accumulated non-capital losses totalling $1,463,000 in Canada and net operating losses of $5,853,000 in the USA, which are available to carry forward and offset future years’ taxable income. The losses expire in various amounts from 2016 to 2034.

Uncertain Tax Positions

The Company has adopted certain provisions of ASC 740, "Income Taxes", which prescribes a recognition threshold and measurement attribute for the recognition and measurement of tax positions taken or expected to be taken in income tax returns. The provisions also provide guidance on the de-recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, and accounting for interest and penalties associated with tax positions.

The Company files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. The Company’s tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities until the expiration of the respective statutes of limitation. The Company currently has no tax years under examination. The Company is subject to tax examinations by tax authorities for all taxation years commencing after 2014.

At March 31, 2015, the Company does not have an accrual relating to uncertain tax positions. It is not anticipated that unrecognized tax benefits would significantly increase or decrease within 12 months of the reporting date.

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Mar. 31, 2015

COMMITMENTS AND CONTINGENCIES [Text Block]

8.	COMMITMENTS AND CONTINGENCIES

(a)	The Company entered into a license agreement with ANR for an exclusive right on ANR’s patent pending technology, claims and knowhow. In addition to the issuance of 16,035,026 shares (Note 5), the Company agreed to pay a 4% royalty on net revenue on the sales of devices covered by the patent-pending technology and services related to the therapy or use of devices covered by the patent-pending technology.

(b)	On March 7, 2014, the Company entered into a commercial development-to-supply program with Ximedica where Ximedica will design, develop and produce PoNS product solution suitable for clinical trial and commercial sale. Under the program, the Company is responsible for ensuring the device is in compliance with relevant laws and regulations. The agreed budget for phase 1B of development is $499,000 ; phase 2 is $1,065,000 ; Phase 3 and 4 is $1,389,000 and 2 ^nd software development cycle is $586,000, of which $3,099,998 was expensed as research and development since inception to March 31, 2015. The estimated duration of the project is 10 months. Invoices are to be issued monthly for work in progress. The Company can cancel the project at anytime with a written notice at least 30 days prior to the intended date of cancellation. As of March 31, 2015, the Company recorded a prepaid expense of $300,000 to Ximedica which will be applied at the end of the project. During the year ended March 31, 2015, the Company incurred charges of $2,928,217 (March 31, 2014 - $171,781) pursuant to this agreement.

(c)	On January 5, 2015, Wicab filed a complaint against us, two of our directors, Yuri Danilov and Mitch Tyler, and ANR in the U.S. District Court for the Western District of Wisconsin. The complaint contained various state and common law claims arising from Danilov’s and Tyler’s prior employment with Wicab and our two issued patents for the PoNS™ device. The complaint alleged, among other things, that following their departure from Wicab, Danilov and Tyler knowingly filed patent applications for and used ideas and inventions developed at Wicab in violation of various non-competition and confidentiality agreements, and that our two issued patents are therefore rightfully the property of Wicab. The complaint sought an unspecified amount of monetary damages, an injunction preventing us from using the ideas and inventions in the two patents, an order transferring ownership of the patents from us to Wicab, and recovery of costs and attorneys’ fees. The complaint was voluntarily dismissed without prejudice on January 14, 2015.

(d)	On January 27, 2015 we received a demand letter containing allegations that we had entered into a consulting arrangement with the complainants and breached certain of its terms, and used certain intellectual property in the form of business and marketing plans allegedly prepared by the complainants, and seeking damages. On May 7, 2015, Mr. Rainier Maas and Dr. Jochen Scheld filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania seeking monetary damages, and at this point management is unable to determine the outcome of this matter.

RELATED PARTY TRANSACTIONS

12 Months Ended

Mar. 31, 2015

RELATED PARTY TRANSACTIONS [Text Block]

9.	RELATED PARTY TRANSACTIONS

For the year ended March 31, 2015, the Company was a party to the following related party transactions:

During the period ended March 31, 2015, the Company paid $6,610 (March 31, 2014 - $nil ; March 31, 2013 - $nil) in consulting fees to a former director of the Company.

During the period ended March 31, 2015, the Company paid $47,100 (March 31, 2014 - $nil ; March 31, 2013 - $nil) in consulting fees to directors of the Company.

During the period ended March 31, 2015, the Company paid $99,146 (March 31, 2014 - $nil ; March 31, 2013 - $nil) to a company acting as the Company’s corporate advisor and Chief Financial Officer.

During the period ended March 31, 2015, $1,040,854 (March 31, 2014 - $nil ; March 31, 2013 - $nil) was included in research & development expenses as the fair value of stock-based compensation attributed to the options granted to two directors and one advisor for services rendered as non-employee consultants with respect to the design and development of the PoNS device.

During the period ended March 31, 2015, $451,994 (March 31, 2014 - $nil ; March 31, 2013 - $nil) was included in wages & salaries expenses as the fair value of stock-based compensation attributed to options granted to three directors.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

SUPPLEMENTAL CASH FLOW INFORMATION

12 Months Ended

Mar. 31, 2015

SUPPLEMENTAL CASH FLOW INFORMATION [Text Block]

10.

SUPPLEMENTAL CASH FLOW INFORMATION

Investing and financing activities that affect recognized assets or liabilities but that do not result in cash receipts or cash payments are excluded from the consolidated statements of cash flows. During the year ended March 31, 2015, the following transactions were excluded from the consolidated statement of cash flows:

	(a)	The Company issued 2,564,705 common shares valued at $1,000,100 based on the carrying value of the convertible debenture upon its conversion. (Note 4)

	(b)	The Company recorded a beneficial conversion feature of $176,488 in respect of a qualifying transaction recorded in connection with the convertible debenture ( Note 4)

	(c)	The Company recorded a credit to additional paid-in capital of $162,890 representing the carrying values of the net assets acquired in a reverse merger recapitalization transaction. (Note 3).

SUBSEQUENT EVENTS

12 Months Ended

Mar. 31, 2015

SUBSEQUENT EVENTS [Text Block]

11.

SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date of the issuance of the financial statements.

On April 30, 2015 the Company closed a non-brokered private placement (the "Financing") raising gross proceeds of CAD $2,208,110 (approximately USD $1,825,937) by the issuance of 849,273 units (each a "Unit") at a price of CAD $2.60 per Unit (USD $2.15 per Unit). Each Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a "Warrant"). Each whole Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of approximately CAD $3.62 per share (USD $3.00 per share) for a period of thirty-six (36) months from the closing date of the Financing.

The Company paid a cash finder’s fee of CAD101,494 (USD $84,074) in connection with this Financing, as well as 27,396 finder’s warrants (the "Finder’s Warrants"). Each Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of CAD $3.62 per share (USD $3.00 per share) for a period of thirty-six (36) months from the closing date of the Financing.

On April 29, 2015, 14,400 finder’s warrants were exercised for gross proceeds of CAD $14,400.

CORRECTION OF AN ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS

12 Months Ended

Mar. 31, 2015

CORRECTION OF AN ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS [Text Block]

12.

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

The Company’s previously issued financial statements have been restated to reflect the correction of an error in the re-measurement of non-employee stock option awards that had yet to vest.

Previously, the Company had recorded the stock-based compensation for the fiscal year ended March 31, 2015 based on the fair value of the awards on their respective grant dates. Under the provisions of ASC 505-50, the Company is required to measure stock-based compensation for non-employees at the earlier of the performance commitment date or the date that the services have been completed. A performance commitment date exists only when the counterparty has sufficient disincentive not to complete. Otherwise, the Company is required to re-measure unvested non-employee options at their respective fair values until the services have been or once the options have vested. Under the terms of the Company’s stock option awards to non-employees, there were no performance disincentives. As a result the Company is required to re-measure its non-employee awards until they have vested. See Note 2 “Significant Accounting Policies - Stock Based Compensation”.

The correction of the error is presented in the Company’s consolidated financial statements for the year ended March 31, 2015 as follows:

		As Originally Reported			Adjustment			As Restated
Research & development expenses	$	3,828,775		$	671,298		$	4,500,073
Net loss for the year	$	8,894,555		$	943,762		$	9,838,317
Comprehensive loss for the year	$	9,866,195		$	943,762		$	10,809,957
Basic and diluted loss per share	$	(0.16	)	$	(0.01	)	$	(0.17	)
Additional paid-in capital		1,490,790		$	943,762		$	2,434,552
Accumulated deficit	$	(18,479,689	)	$	(943,762	)		(19,423,451	)
Consulting fees	$	1,085,606		$	272,464		$	1,358,070

This error correction had no impact on the cash flows of the Company. Accordingly, there is no restatement affecting the Company’s net cash used in operating activities or net change in cash or cash equivalents for the reporting period. This error correction also had no impact on the Company’s opening accumulated deficit figure for the year ended March 31, 2015. Accordingly, there is no restatement affecting the Company’s opening accumulated deficit for the year ended March 31, 2015.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Mar. 31, 2015

Basis of Presentation and Liquidity [Policy Text Block]

Basis of Presentation and Liquidity

Use of Estimates [Policy Text Block]

Use of Estimates

Principles of Consolidation [Policy Text Block]

Principles of Consolidation

Cash and Cash Equivalents [Policy Text Block]

Cash and Cash Equivalents

Cash and cash equivalents comprise cash at banks and on hand, and short-term highly liquid investments that have an insignificant interest rate risk and an original maturity of 3 months or less.

Short-term investment [Policy Text Block]

Short-term investment

Concentrations of Credit Risk [Policy Text Block]

Concentrations of Credit Risk

Stock-Based Compensation [Policy Text Block]

Stock-Based Compensation

The Company accounts for all stock-based payments and awards under the fair value based method. The Company recognizes its stock-based compensation using the accelerated attribution method.

Foreign Exchange [Policy Text Block]

Foreign Exchange

The functional currency of the Company and Helius Canada is the Canadian Dollar and the functional currency of Neuro is the United States Dollars. The Company’s reporting currency is the US dollar.

Net Loss per Common Share [Policy Text Block]

Net Loss per Common Share

Fair Value of Financial Assets and Liabilities [Policy Text Block]

Fair Value of Financial Assets and Liabilities

Level 1 - Quoted prices in active markets for identical assets or liabilities;

Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and

Cash and cash equivalents and short-term investment are measured using Level 1 inputs.

A summary of the Company’s Level 3 liabilities for the fiscal years ended March 31, 2015 and 2014 are as follows:

	March 31,2015	March 31, 2014
	$	$

Non-employee options (Note 6(a))
Beginning fair value	-	-
Issuance	767,879	-
Reallocation of vested non-employee options	74,190	-
Change in fair value	739,375	-
Ending fair value of Level 3 liability	1,581,444	-

Income Taxes [Policy Text Block]

Income Taxes

Research and Development Expenses [Policy Text Block]

Research and Development Expenses

Derivative Liabilities [Policy Text Block]

Derivative Liabilities

The Company uses the Black-Scholes option valuation model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement.

Recent Accounting Pronouncements [Policy Text Block]

Recent Accounting Pronouncements

SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Mar. 31, 2015

Fair Value, by Balance Sheet Grouping [Table Text Block]

	March 31,2015	March 31, 2014
	$	$

Non-employee options (Note 6(a))
Beginning fair value	-	-
Issuance	767,879	-
Reallocation of vested non-employee options	74,190	-
Change in fair value	739,375	-
Ending fair value of Level 3 liability	1,581,444	-

SHARE BASED PAYMENTS (Tables)

12 Months Ended

Mar. 31, 2015

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

				Weighted
				Average		Aggregate
				Exercise Price		Intrinsic Value
	Number			(CAD)		(CAD)
Balance, March 31, 2013	-			-
Granted	3,230,031		$	0.0003	$	-

Balance, March 31, 2014	3,230,031		$	0.0003	$	-
Granted	4,920,000		$	1.14	$	-
Exercised	(3,230,031	)	$	0.0003	$	-

Balance outstanding at March 31, 2015	4,920,000		$	1.14	$	10,120,000

Balance exercisable at March 31, 2015	2,015,001		$	1.41	$	7,757,667

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

		Options
		outstanding
		remaining
		contractual life		Exercise		Grant date fair	Number of options
Number of options	Expiry date	(years)		Price (CAD)		value (CAD)	exercisable

3,520,000	June 18, 2019	4.22	$	0.60	$	0.23	1,173,333
250,000	June 20, 2019	4.22	$	0.60	$	0.23	125,000
100,000	July 14, 2017	2.29	$	2.52	$	1.06	100,000
450,000	December 8, 2019	4.69	$	2.92	$	1.65	450,000
100,000	December 8, 2019	4.69	$	2.92	$	1.49	33,334
400,000	December 8, 2019	4.69	$	2.96	$	1.56	100,000
100,000	March 16, 2020	4.96	$	3.20	$	1.61	33,334
4,920,000							2,015,001

Schedule of Non-Employee Share-based Compensation Arrangements Fair Values [Table Text Block]

	2015	2014
	$	$

Fair value of non-employee options, beginning of the period	-	-
Fair value of non-employee options, at issuance	767,879	-
Reallocation of vested non-employee options	74,190
Change in fair value of non-employee stock options during the period	739,375	-

Fair value of non-employee options, end of the period	1,581,444	-

Stock-Based Compensation Related to the Grant of Each of Employee and Non-Employee Options [Table Text Block]

Date of grant	Number		2015	2014	2013
			(restated) $	$	$

Employee options
April 1, 2013	930,031		-	247,075	-
October 30, 2013	2,300,000		50,303	560,082	-
June 19, 2014	1,970,000		165,996	-	-
July 14, 2014	75,000		74,190	-	-
December 8, 2014	100,000		43,229	-	-
December 8, 2014	400,000		135,564	-	-
March 16, 2015	100,000		41,987	-	-
	5,875,031		511,269	807,157	-
Options exercised	(3,230,031	)	-	-	-
	2,645,000		511,269
Non-employee
options
June 19, 2014	1,800,000		1,158,822	-	-
July 14, 2014	25,000		24,730	-	-
December 8, 2014	450,000		646,055	-	-
	2,275,000		1,824,607	-	-

	4,920,000		2,340,876	807,157	-

Share-Based Payments Classified in the Companys Statement of Loss [Table Text Block]

	2015	2014	2013
	(restated) $	$	$

Consulting fees	1,167,281	807,157	4,250,000
Research and development	721,601	-	4,250,000
Wages and salaries	451,994	-

	2,340,876	807,157	8,500,000

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

		March 31, 2015	March 31, 2014
Stock Price	CAD$	0.50 - 3.18	0.27
Exercise Price	CAD$	0.60 - 3.20	0.0003
Risk-free interest rate (%)		0.53 - 1.42	1.20 - 1.65
Dividend yield (%)		0.00	0.00
Expected volatility (%)		67.85	97.73 - 116.82
Expected option life (years)		3.00 - 5.00	4.33 - 5.00

Schedule of Share-based Payment Award, Warrants, Valuation Assumptions [Table Text Block]

Stock price		CAD$0.50
Exercise price		CAD$1.00
Risk-free interest rate (%)		1.09
Dividend yield (%)		-
Expected volatility (%)		67.85
Expected option life (years)		1.17

Schedule of Stockholder's Equity Note Warrants Or Rights Activity [Table Text Block]

			Warrants Outstanding
	Number of		Weighted Average Exercise Price
	warrants
Balance, March 31, 2013 and 2014	-	$	-
Granted	8,444,400	$	CAD1.00
Balance, March 31, 2015	8,444,400	$	CAD1.00

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

		Grant date
Number of warrants outstanding	Exercise Price (CAD)	Fair value (CAD)	Expiry Date
7,620,000	$1.00	$0.0899	May 30, 2016
824,400	$1.00	$0.0899	May 30, 2016

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

INCOME TAXES (Tables)

12 Months Ended

Mar. 31, 2015

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

	2015	2014	2013
	$	$	$

U.S	9,301,988	1,067,284	8,517,850
Non-U.S.	536,329	-	-

	9,838,317	1,067,284	8.517,750

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	2015	2014	2013
	$	$	$
Statutory tax rate	34.00%	25.00%	25.00%
Loss before income taxes	(9,838,317)	(1,067,284)	(8,517,850)
Expected income tax recovery	(3,345,000)	(270,000)	(2,151,000)
Increase (decrease) in income tax recovery resulting from:
Derivative liability	251,000	-
Share based payments	796,000	275,000	2,890,000
Other permanent difference	12,000	-	-
Share issue costs	(140,000)	-
Effect of change in statutory rate	(41,000)	(93,000)	(745,000)
Effect of foreign exchange	89,000	-
Foreign income taxed at foreign rate	14,000	-
Increase in valuation allowance	2,364,000	88,000	6,000
Income tax expense	-	-	-

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	2015		2014		2013
	$		$		$


Deferred income tax assets (liabilities)
Operating losses carried forward	2,074,000		94,000		6,000
Intangible costs	285,000
Share issuance costs	99,000		-
Valuation allowance	(2,458,000	)	(94,000	)	(6,000	)


Net deferred income tax asset	-		-		-

CORRECTION OF AN ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)

12 Months Ended

Mar. 31, 2015

Schedule of Error Corrections and Prior Period Adjustments in Statement of Operations [Table Text Block]

Cash and cash equivalents	$	23,904
Receivables		1,644
Bridge loan receivable		150,000
Prepaid expenses		5,970
Accounts payable and accrued liabilities		(18,628	)
	$	162,890

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

		As Originally Reported			Adjustment			As Restated
Research & development expenses	$	3,828,775		$	671,298		$	4,500,073
Net loss for the year	$	8,894,555		$	943,762		$	9,838,317
Comprehensive loss for the year	$	9,866,195		$	943,762		$	10,809,957
Basic and diluted loss per share	$	(0.16	)	$	(0.01	)	$	(0.17	)
Additional paid-in capital		1,490,790		$	943,762		$	2,434,552
Accumulated deficit	$	(18,479,689	)	$	(943,762	)		(19,423,451	)
Consulting fees	$	1,085,606		$	272,464		$	1,358,070

BASIS OF PRESENTATION (Narrative) (Details)	12 Months Ended
BASIS OF PRESENTATION (Narrative) (Details)	Mar. 31, 2015
Basis Of Presentation 1	100.00%

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	12 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	Mar. 31, 2015 USD ($) mo shares
Significant Accounting Policies 1	$ 9,838,317
Significant Accounting Policies 2	19,423,451
Significant Accounting Policies 3	9,585,134
Significant Accounting Policies 4	8,517,850
Significant Accounting Policies 5	418,893
Significant Accounting Policies 6	$ 15,968
Significant Accounting Policies 7 \| mo	3
Significant Accounting Policies 8	$ 378,000
Significant Accounting Policies 9	0.25%
Significant Accounting Policies 10	$ 573,917
Significant Accounting Policies 11 \| shares	4,920,000
Significant Accounting Policies 12	3,230,031
Significant Accounting Policies 13	2,013
Significant Accounting Policies 14	0
Significant Accounting Policies 15 \| shares	8,444,400
Significant Accounting Policies 16	0
Significant Accounting Policies 17	50.00%
Significant Accounting Policies 18 \| mo	12

RECAPITALIZATION (Narrative) (Details) - 12 months ended Mar. 31, 2015	USD ($) shares	CAD ($) $ / shares shares
Recapitalization 1	100.00%	100.00%
Recapitalization 2 \| shares	35,300,083	35,300,083
Recapitalization 3	$ 150,000
Recapitalization 4	8.00%	8.00%
Recapitalization 5	$ 162,890
Recapitalization 6 \| shares	15,240,000	15,240,000
Recapitalization 7 \| $ / shares		$ 0.50
Recapitalization 8	$ 7,016,002
Recapitalization 9		$ 7,620,000
Recapitalization 10		1.00
Recapitalization 11	$ 379,806
Recapitalization 12		$ 412,200
Recapitalization 13	824,400	824,400
Recapitalization 14 \| $ / shares		$ 1.00

CONVERTIBLE DEBENTURE (Narrative) (Details)	12 Months Ended
CONVERTIBLE DEBENTURE (Narrative) (Details)	Mar. 31, 2015 USD ($) shares
Convertible Debenture 1	8.00%
Convertible Debenture 2	$ 1,000,100
Convertible Debenture 3	$ 2,000,000
Convertible Debenture 4	85.00%
Convertible Debenture 5	$ 8,500,000
Convertible Debenture 6	85.00%
Convertible Debenture 7	$ 176,488
Convertible Debenture 8 \| shares	2,564,705
Convertible Debenture 9	$ 11,131

COMMON STOCK (Narrative) (Details) - 12 months ended Mar. 31, 2015	USD ($) mo yr shares	CAD ($) mo yr $ / shares shares
Common Stock 1 \| shares	16,035,026	16,035,026
Common Stock 2	$ 5,000
Common Stock 3	4,250,000
Common Stock 4	$ 4,250,000
Common Stock 5 \| shares	16,035,026	16,035,026
Common Stock 6	$ 5,000
Common Stock 7	$ 4,250,000
Common Stock 8 \| shares	2,300,000	2,300,000
Common Stock 9 \| shares	2,300,000	2,300,000
Common Stock 10	$ 717
Common Stock 11 \| shares	930,031	930,031
Common Stock 12 \| shares	930,031	930,031
Common Stock 13	$ 290
Common Stock 14 \| shares	32,070,052	32,070,052
Common Stock 15 \| yr	3	3
Common Stock 16	10.00%	10.00%
Common Stock 17	15.00%	15.00%
Common Stock 18 \| mo	6	6
Common Stock 19 \| shares	35,300,083	35,300,083
Common Stock 20 \| $ / shares		$ 0.50
Common Stock 21 \| shares	15,240,000	15,240,000
Common Stock 22	$ 7,016,002
Common Stock 23		$ 7,620,000
Common Stock 24 \| yr	2	2
Common Stock 25		$ 1.00
Common Stock 26	$ 578,961

SHARE BASED PAYMENTS (Narrative) (Details) - 12 months ended Mar. 31, 2015	USD ($) yr shares	CAD ($) yr $ / shares shares
Share Based Payments 1 \| shares	12,108,016	12,108,016
Share Based Payments 2 \| shares	930,031	930,031
Share Based Payments 3 \| yr	10	10
Share Based Payments 4 \| shares	654,481	654,481
Share Based Payments 5 \| shares	930,031	930,031
Share Based Payments 6 \| shares	2,300,000	2,300,000
Share Based Payments 7 \| yr	10	10
Share Based Payments 8 \| shares	1,150,000	1,150,000
Share Based Payments 9 \| shares	1,150,000	1,150,000
Share Based Payments 10 \| shares	2,300,000	2,300,000
Share Based Payments 11 \| shares	2,300,000	2,300,000
Share Based Payments 12 \| shares	3,520,000	3,520,000
Share Based Payments 13		$ 0.60
Share Based Payments 14 \| yr	5	5
Share Based Payments 15 \| shares	250,000	250,000
Share Based Payments 16		$ 0.60
Share Based Payments 17 \| yr	5	5
Share Based Payments 18	12.50%	12.50%
Share Based Payments 19	87.50%	87.50%
Share Based Payments 20	12.50%	12.50%
Share Based Payments 21 \| shares	100,000	100,000
Share Based Payments 22		$ 2.52
Share Based Payments 23 \| yr	3	3
Share Based Payments 24	25.00%	25.00%
Share Based Payments 25	25.00%	25.00%
Share Based Payments 26 \| shares	450,000	450,000
Share Based Payments 27		$ 2.92
Share Based Payments 28 \| yr	5	5
Share Based Payments 29 \| shares	100,000	100,000
Share Based Payments 30		$ 2.92
Share Based Payments 31 \| yr	5	5
Share Based Payments 32 \| shares	400,000	400,000
Share Based Payments 33		$ 2.96
Share Based Payments 34 \| yr	5	5
Share Based Payments 35	25.00%	25.00%
Share Based Payments 36	25.00%	25.00%
Share Based Payments 37 \| shares	100,000	100,000
Share Based Payments 38		$ 3.20
Share Based Payments 39 \| yr	5	5
Share Based Payments 40		$ 0.54
Share Based Payments 41		1.06
Share Based Payments 42		$ 1.14
Share Based Payments 43	1.08%	1.08%
Share Based Payments 44 \| yr	4.1	4.1
Share Based Payments 45	67.85%	67.85%
Share Based Payments 46	0.00%	0.00%
Share Based Payments 105	$ 2,303,664
Share Based Payments 106	2,070,656
Share Based Payments 107	$ 233,008
Share Based Payments 108 \| $ / shares		$ 0.50
Share Based Payments 109 \| shares	15,240,000	15,240,000
Share Based Payments 110		$ 7,620,000
Share Based Payments 111 \| yr	2	2
Share Based Payments 112		$ 1.00
Share Based Payments 113	$ 578,961
Share Based Payments 114	824,400	824,400
Share Based Payments 115		$ 1.00
Share Based Payments 116 \| yr	2	2
Share Based Payments 117	$ 67,709

INCOME TAXES (Narrative) (Details)	12 Months Ended
INCOME TAXES (Narrative) (Details)	Mar. 31, 2015 USD ($) mo
Income Taxes 1	$ 1,463,000
Income Taxes 2	$ 5,853,000
Income Taxes 3 \| mo	12

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	12 Months Ended
COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	Mar. 31, 2015 USD ($) mo d shares
Commitments And Contingencies 1 \| shares	16,035,026
Commitments And Contingencies 2	4.00%
Commitments And Contingencies 3	$ 499,000
Commitments And Contingencies 4	1,065,000
Commitments And Contingencies 5	1,389,000
Commitments And Contingencies 6	586,000
Commitments And Contingencies 7	$ 3,099,998
Commitments And Contingencies 8 \| mo	10
Commitments And Contingencies 9 \| d	30
Commitments And Contingencies 10	$ 300,000
Commitments And Contingencies 11	2,928,217
Commitments And Contingencies 12	$ 171,781

RELATED PARTY TRANSACTIONS (Narrative) (Details)	12 Months Ended
RELATED PARTY TRANSACTIONS (Narrative) (Details)	Mar. 31, 2015 USD ($)
Related Party Transactions 1	$ 6,610
Related Party Transactions 2	0
Related Party Transactions 3	0
Related Party Transactions 4	47,100
Related Party Transactions 5	0
Related Party Transactions 6	0
Related Party Transactions 7	99,146
Related Party Transactions 8	0
Related Party Transactions 9	0
Related Party Transactions 10	1,040,854
Related Party Transactions 11	0
Related Party Transactions 12	0
Related Party Transactions 13	451,994
Related Party Transactions 14	0
Related Party Transactions 15	$ 0

SUPPLEMENTAL CASH FLOW INFORMATION (Narrative) (Details)	12 Months Ended
	Mar. 31, 2015 USD ($) shares
Supplemental Cash Flow Information 1 \| shares	2,564,705
Supplemental Cash Flow Information 2	$ 1,000,100
Supplemental Cash Flow Information 3	176,488
Supplemental Cash Flow Information 4	$ 162,890

SUBSEQUENT EVENTS (Narrative) (Details) - 12 months ended Mar. 31, 2015	USD ($) $ / shares shares	CAD ($) $ / shares shares
Subsequent Events 1		$ 2,208,110
Subsequent Events 2	$ 1,825,937
Subsequent Events 3 \| shares	849,273	849,273
Subsequent Events 4		$ 2.60
Subsequent Events 5	$ 2.15
Subsequent Events 6 \| $ / shares		$ 3.62
Subsequent Events 7 \| $ / shares	$ 3.00
Subsequent Events 8		$ 101,494
Subsequent Events 9	$ 84,074
Subsequent Events 10	27,396	27,396
Subsequent Events 11 \| $ / shares		$ 3.62
Subsequent Events 12 \| $ / shares	$ 3.00
Subsequent Events 13	14,400	14,400
Subsequent Events 14		$ 14,400

Fair Value, by Balance Sheet Grouping (Details)	12 Months Ended
Fair Value, by Balance Sheet Grouping (Details)	Mar. 31, 2015 USD ($) shares
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 1	$ 0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 2	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 3	$ 767,879
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 4 \| shares	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 5	$ 74,190
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 6	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 7	739,375
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 8	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 9	1,581,444
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 10	$ 0

Schedule of Share-based Compensation, Stock Options, Activity (Details)	12 Months Ended
	Mar. 31, 2015 USD ($)
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 1	$ 0
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 2	0
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 3	$ 3,230,031
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 4	0.0003
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 5	$ 0
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 6	$ 3,230,031
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 7	0.0003
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 8	$ 0
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 9	$ 4,920,000
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 10	1.14
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 11	$ 0
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 12	$ (3,230,031)
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 13	0.0003
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 14	$ 0
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 15	$ 4,920,000
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 16	1.14
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 17	$ 10,120,000
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 18	$ 2,015,001
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 19	1.41
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 20	$ 7,757,667

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details)	12 Months Ended
	Mar. 31, 2015 USD ($)
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 1	$ 3,520,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 2	4.22
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 3	0.60
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 4	0.23
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 5	$ 1,173,333
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 6	$ 250,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 7	4.22
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 8	0.60
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 9	0.23
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 10	$ 125,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 11	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 12	2.29
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 13	2.52
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 14	1.06
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 15	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 16	$ 450,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 17	4.69
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 18	2.92
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 19	1.65
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 20	$ 450,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 21	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 22	4.69
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 23	2.92
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 24	1.49
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 25	$ 33,334
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 26	$ 400,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 27	4.69
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 28	2.96
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 29	1.56
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 30	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 31	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 32	4.96
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 33	3.20
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 34	1.61
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 35	$ 33,334
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 36	4,920,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 37	$ 2,015,001

Stock-Based Compensation Related to the Grant of Each of Employee and Non-Employee Options (Details)	12 Months Ended
	Mar. 31, 2015 USD ($)
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 1	$ 930,031
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 2	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 3	247,075
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 4	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 5	2,300,000
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 6	50,303
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 7	560,082
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 8	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 9	1,970,000
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 10	165,996
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 11	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 12	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 13	75,000
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 14	74,190
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 15	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 16	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 17	100,000
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 18	43,229
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 19	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 20	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 21	400,000
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 22	135,564
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 23	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 24	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 25	100,000
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 26	41,987
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 27	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 28	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 29	5,875,031
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 30	511,269
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 31	807,157
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 32	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 33	(3,230,031)
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 34	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 35	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 36	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 37	2,645,000
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 38	511,269
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 39	1,800,000
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 40	1,158,822
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 41	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 42	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 43	25,000
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 44	24,730
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 45	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 46	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 47	450,000
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 48	646,055
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 49	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 50	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 51	2,275,000
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 52	1,824,607
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 53	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 54	0
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 55	4,920,000
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 56	2,340,876
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 57	807,157
Share Based Payments Stock-based Compensation Related To The Grant Of Each Of Employee And Non-employee Options 58	$ 0

Share-Based Payments Classified in the Companys Statement of Loss (Details)	12 Months Ended
	Mar. 31, 2015 USD ($)
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 1	$ 1,167,281
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 2	807,157
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 3	4,250,000
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 4	721,601
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 5	0
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 6	4,250,000
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 7	451,994
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 8	0
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 9	2,340,876
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 10	807,157
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 11	$ 8,500,000

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	12 Months Ended
	Mar. 31, 2015
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 1	0.50
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 2	3.18
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 3	0.27
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 4	0.60
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 5	3.20
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 6	0.0003
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 7	0.53
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 8	1.42
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 9	1.20
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 10	1.65
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 11	0.00
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 12	0.00
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 13	67.85
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 14	97.73
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 15	116.82
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 16	3.00
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 17	5.00
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 18	4.33
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 19	5.00

Schedule of Share-based Payment Award, Warrants, Valuation Assumptions (Details)	12 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2015 CAD ($)
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 1		$ 0.50
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 2		$ 1.00
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 3	1.09	1.09
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 4	$ 0
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 5	67.85	67.85
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 6	1.17	1.17

Schedule of Stockholder's Equity Note Warrants Or Rights Activity (Details) - 12 months ended Mar. 31, 2015	USD ($)	CAD ($)
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 1	$ 0
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 2	0
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 3	8,444,400
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 4		$ 1.00
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 5	$ 8,444,400
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 6		$ 1.00

Schedule of Stockholders' Equity Note, Warrants or Rights (Details)	12 Months Ended
	Mar. 31, 2015 USD ($)
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 1	$ 7,620,000
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 2	1.00
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 3	0.0899
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 4	824,400
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 5	1.00
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 6	$ 0.0899

Schedule of Income before Income Tax, Domestic and Foreign (Details)	12 Months Ended
	Mar. 31, 2015 USD ($)
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 1	$ 9,301,988
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 2	1,067,284
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 3	8,517,850
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 4	536,329
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 5	0
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 6	0
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 7	9,838,317
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 8	$ 1,067,284
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 9	8.517

Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Mar. 31, 2015 USD ($)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 1	34.00%
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 2	25.00%
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 3	25.00%
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 4	$ (9,838,317)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 5	(1,067,284)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 6	(8,517,850)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 7	(3,345,000)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 8	(270,000)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 9	(2,151,000)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 10	251,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 11	0
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 12	796,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 13	275,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 14	2,890,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 15	12,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 16	0
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 17	0
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 18	(140,000)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 19	0
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 20	(41,000)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 21	(93,000)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 22	(745,000)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 23	89,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 24	0
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 25	14,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 26	0
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 27	2,364,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 28	88,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 29	6,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 30	0
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 31	0
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 32	$ 0

Schedule of Deferred Tax Assets and Liabilities (Details)	12 Months Ended
	Mar. 31, 2015 USD ($)
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 1	$ 2,074,000
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 2	94,000
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 3	6,000
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 4	285,000
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 5	99,000
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 6	0
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 7	(2,458,000)
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 8	(94,000)
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 9	(6,000)
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 10	0
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 11	0
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 12	$ 0

Schedule of Error Corrections and Prior Period Adjustments in Statement of Operations (Details)	12 Months Ended
	Mar. 31, 2015 USD ($)
Recapitalization Net Assets Of Helius Acquired 1	$ 23,904
Recapitalization Net Assets Of Helius Acquired 2	1,644
Recapitalization Net Assets Of Helius Acquired 3	150,000
Recapitalization Net Assets Of Helius Acquired 4	5,970
Recapitalization Net Assets Of Helius Acquired 5	(18,628)
Recapitalization Net Assets Of Helius Acquired 6	$ 162,890

Schedule of Error Corrections and Prior Period Adjustments (Details)	12 Months Ended
	Mar. 31, 2015 USD ($)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 1	$ 3,828,775
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 2	671,298
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 3	4,500,073
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 4	8,894,555
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 5	943,762
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 6	9,838,317
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 7	9,866,195
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 8	943,762
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 9	$ 10,809,957
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 10	(0.16)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 11	(0.01)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 12	(0.17)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 13	$ 1,490,790
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 14	943,762
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 15	2,434,552
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 16	(18,479,689)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 17	(943,762)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 18	(19,423,451)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 19	1,085,606
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 20	272,464
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 21	$ 1,358,070